Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 2
2004 3
2010 1
2011 1
2014 1
2015 1
2016 2
2017 6
2018 8
2019 14
2020 13
2021 22
2022 15
2023 13
2024 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Manuilov D, Suri V, An Q, Da B, Flaherty J, Osinusi A, Liu Y, Merle U, Schulze Zur Wiesch J, Zeuzem S, Ciesek S, Cornberg M, Lampertico P; MYR 301 Study Group. Wedemeyer H, et al. Among authors: da b. N Engl J Med. 2023 Jul 6;389(1):22-32. doi: 10.1056/NEJMoa2213429. Epub 2023 Jun 22. N Engl J Med. 2023. PMID: 37345876 Free article. Clinical Trial.
Noncirrhotic portal hypertension.
Da BL, Koh C, Heller T. Da BL, et al. Curr Opin Gastroenterol. 2018 May;34(3):140-145. doi: 10.1097/MOG.0000000000000433. Curr Opin Gastroenterol. 2018. PMID: 29465431 Review.
Reply.
Da BL, Koh C, Heller T. Da BL, et al. Hepatology. 2020 Jan;71(1):397-398. doi: 10.1002/hep.30955. Epub 2019 Dec 24. Hepatology. 2020. PMID: 31531987 No abstract available.
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.
Asselah T, Chulanov V, Lampertico P, Wedemeyer H, Streinu-Cercel A, Pântea V, Lazar S, Placinta G, Gherlan GS, Bogomolov P, Stepanova T, Morozov V, Syutkin V, Sagalova O, Manuilov D, Mercier RC, Ye L, Da BL, Chee G, Lau AH, Osinusi A, Bourliere M, Ratziu V, Pol S, Hilleret MN, Zoulim F. Asselah T, et al. Among authors: da bl. N Engl J Med. 2024 Jul 11;391(2):133-143. doi: 10.1056/NEJMoa2314134. Epub 2024 Jun 6. N Engl J Med. 2024. PMID: 38842520 Clinical Trial.
HBV/HDV Coinfection: A Challenge for Therapeutics.
Koh C, Da BL, Glenn JS. Koh C, et al. Among authors: da bl. Clin Liver Dis. 2019 Aug;23(3):557-572. doi: 10.1016/j.cld.2019.04.005. Epub 2019 May 24. Clin Liver Dis. 2019. PMID: 31266627 Free PMC article. Review.
Pathogenesis to management of hepatocellular carcinoma.
Da BL, Suchman KI, Lau L, Rabiee A, He AR, Shetty K, Yu H, Wong LL, Amdur RL, Crawford JM, Fox SS, Grimaldi GM, Shah PK, Weinstein J, Bernstein D, Satapathy SK, Chambwe N, Xiang X, Mishra L. Da BL, et al. Genes Cancer. 2022 Dec 13;13:72-87. doi: 10.18632/genesandcancer.226. eCollection 2022. Genes Cancer. 2022. PMID: 36533190 Free PMC article. Review.
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.
Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Ciesek S, Manuilov D, Mercier RC, Da BL, Chee GM, Li M, Flaherty JF, Lau AH, Osinusi A, Schulze Zur Wiesch J, Cornberg M, Zeuzem S, Lampertico P. Wedemeyer H, et al. Among authors: da bl. J Hepatol. 2024 Oct;81(4):621-629. doi: 10.1016/j.jhep.2024.05.001. Epub 2024 May 9. J Hepatol. 2024. PMID: 38734383 Free article. Clinical Trial.
102 results